Regulation of Hippo/YAP signaling and Esophageal Squamous Carcinoma progression by an E3 ubiquitin ligase PARK2
Conclusion: Clinical sample analysis and mechanistic study have validated PARK2 as a tumor suppressor for ESCC. Multivariate Cox proportional regression analysis further revealed that PARK2 is an independent prognostic factor for the overall survival of ESCC patients. Cellular and molecular mechanisms in this study showed that PARK2 associated with YAP protein in the cytosol, promoted YAP ubiquitination and proteasome-dependent degradation in ESCC cells. Therefore, as a novel modulator for Hippo signaling, modulation of PARK2 activity or gene expression level could be an appealing strategy to treat esophageal.
Source: Theranostics - Category: Molecular Biology Authors: Xiaofeng Zhou, Yajie Li, Weilong Wang, Sujie Wang, Jinghan Hou, Aijia Zhang, Benjie Lv, Can Gao, Ziyi Yan, Dan Pang, Kui Lu, Nor Hazwani Ahmad, Lidong Wang, Jian Zhu, Lichen Zhang, Ting Zhuang, Xiumin Li Tags: Research Paper Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | China Health | Esophagus Cancer | Genetics | Molecular Biology | Skin Cancer | Squamous Cell Carcinoma | Study